WSFS
KALV

Wilmington Savings Fund Society’s KalVista Pharmaceuticals KALV Stock Holding History

Wilmington Savings Fund Society’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-415
Closed -$4.69K – 1741
2025
Q2 		$4.69K Hold
415
– – ﹤0.01% 1768
2025
Q1 		$4.79K Hold
415
– – ﹤0.01% 1789
2024
Q4 		$3.52K Buy
+415
New +$4.3K ﹤0.01% 1855

Other funds holding KALV

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Wilmington Savings Fund Society's KALV Position: Q3 2025 in Review

Wilmington Savings Fund Society sold out of KalVista Pharmaceuticals (KALV) in Q3 2025, closing a stake of 415 shares — an estimated $4.69K sold.

Wilmington Savings Fund Society first reported a position in KALV in Q4 2024 and held it in 3 quarters. The position peaked at $4.79K in Q1 2025. 145 funds tracked by Wall St. Rank hold KALV as of Q3 2025.

  • Wilmington Savings Fund Society reported no remaining KalVista Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Wilmington Savings Fund Society sold 415 KalVista Pharmaceuticals shares in Q3 2025, an estimated $4.69K.
  • Wilmington Savings Fund Society first reported a position in KalVista Pharmaceuticals in Q4 2024 and held it in 3 quarters.
  • Wilmington Savings Fund Society's KalVista Pharmaceuticals position peaked at $4.79K in Q1 2025.
  • 145 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q3 2025.

Based on Wilmington Savings Fund Society's 13F filing for Q3 2025, filed 28 Oct 2025.